Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
暂无分享,去创建一个
S. Ramalingam | A. Argiris | M. Egorin | C. Belani | R. Stoller | J. Zwiebel | T. Lagattuta | R. Parise | D. Potter | Ramesh K. Ramananthan | L. A. Musguire
[1] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[2] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[3] S. Ramalingam,et al. A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[4] J. Issa,et al. PML-RARα and AML1–ETO translocations are rarely associated with methylation of the RARβ2 promoter , 2006, Annals of Hematology.
[5] T. Kuzel,et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Seto,et al. Acetylation and deacetylation of non-histone proteins. , 2005, Gene.
[7] H. Yamaguchi,et al. Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 , 2005, Clinical Cancer Research.
[8] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Hess-Stumpp. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.
[10] K. C. Yeh,et al. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation , 1978, Journal of Pharmacokinetics and Biopharmaceutics.
[11] J. Arts,et al. Histone Deacetylase Inhibitors: From Chromatin Remodelling to Experimental Cancer Therapeutics , 2005 .
[12] Y. Pommier,et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.
[13] J. Arts,et al. Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.
[14] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L. Schwartz,et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] K. Bhalla,et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. , 2003, Blood.
[17] K. Glaser,et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.
[18] M. Egorin,et al. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[19] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[20] L. Devy,et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling , 2002, Oncogene.
[21] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[22] S. Grant,et al. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) , 2002, Leukemia.
[23] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[24] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Pardee,et al. Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment , 2000, Molecular medicine.
[26] P. Marks,et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[28] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[29] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[30] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[31] E. Zuhowski,et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Marks,et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Workman,et al. Alteration of nucleosome structure as a mechanism of transcriptional regulation. , 1998, Annual review of biochemistry.
[34] Kearns Cm,et al. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. , 1997 .
[35] M. Egorin,et al. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. , 1997, Seminars in oncology.
[36] R A Rifkind,et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] W J Jusko,et al. LAGRAN program for area and moments in pharmacokinetic analysis. , 1983, Computer programs in biomedicine.